Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Vaxcyte, Inc. director Moncef Slaoui reported receiving a new stock option grant covering 26,061 shares of common stock. The option has an exercise price of $52.11 per share and expires on June 22, 2036.
The award was granted at no cost and is classified as a compensation-related grant, not an open‑market purchase or sale. According to the vesting terms, one‑third of the option will vest on June 17, 2027, with the remaining portion vesting in equal monthly installments over the following 24 months, contingent on his continued service with the company.
Vaxcyte, Inc. director Moncef Slaoui filed an initial Form 3 as a reporting person and disclosed that he currently holds no securities of the company. The filing shows total beneficial ownership of 0 shares of Vaxcyte common stock following the reported position and lists no purchase or sale transactions.
Vaxcyte, Inc. announced a planned change on its board of directors. On June 17, 2026, long‑serving director Jacks Lee retired from the board, with the company stating his retirement was not due to any disagreement or dispute. He will continue to support Vaxcyte under a consulting agreement focused on global strategic supply and manufacturing operations.
That same day, the board appointed Moncef Slaoui as a Class II independent director, effective immediately, with a term running until the 2028 annual stockholder meeting. He qualifies as an independent director under Nasdaq Rule 5605(a)(2), and the company reports no related‑party transactions requiring disclosure. Slaoui will be compensated under Vaxcyte’s non‑employee director compensation program, which currently sets the equivalent value of the annual equity grant for each director at $430,000, and he has entered into the company’s standard indemnification agreement.
Vaxcyte, Inc. director and CEO Grant Pickering reported a mix of stock option exercise and share sales in Common Stock on June 18, 2026. He exercised stock options for 225 shares at $1.79 per share and separately reported open-market sales totaling 24,461 shares at prices around $52.50 per share.
Two 1,000-share sales were attributed to children’s trusts that hold shares for his son and daughter, while 22,461 shares were sold from his direct holdings. After these transactions, Pickering holds 496,939 shares directly and 135,215 shares indirectly through trusts. The filing notes the sales were completed under a pre-arranged Rule 10b5-1 trading plan adopted on March 3, 2026.
Vaxcyte, Inc. President and CFO Andrew Guggenhime reported a combination of option exercise and share sale. On June 18, 2026, he exercised stock options for 10,000 shares of common stock at $5.35 per share and sold 10,000 shares of common stock at $53.00 per share in an open-market transaction.
The filing notes that the sale was effected under a Rule 10b5-1 trading plan adopted March 4, 2026. Following these transactions, he holds 104,395 shares of common stock directly and 61,850 shares indirectly through ALG 2025 GRAT HOLDINGS LLC, tied to a grantor retained annuity trust. The option related to these 10,000 shares is fully vested and exercisable and has now been exercised.
UBS Financial Services, Inc. submitted a Form 144 notice reporting proposed sales of Common stock tied to option exercises and vested RSUs. The filing lists specific blocks of shares (e.g., 7,751, 5,548, 3,612, 5,325, 2,000, and 225) with transaction dates including 06/18/2026, 09/02/2024, 08/31/2024, 02/28/2025, and 03/02/2025.
The notice identifies the transactions as sales "by issuer" events on NASDAQ and includes prior issuer-issued founder shares and RSU vesting items. Timing and aggregate proceeds are not stated in the excerpt.
Vaxcyte, Inc. director Carlos V. Paya reported new equity awards. He received 2,265 shares of Common Stock underlying restricted stock units (RSUs) at no cost and 11,389 stock options with a $49.56 exercise price, both granted as compensation.
The RSUs fully vest on the earlier of June 15, 2027 or the day before the next annual stockholder meeting, with delivery deferred under Vaxcyte's Nonqualified RSU Deferral Program for Non-Employee Directors. The options vest monthly on the same schedule and expire on June 15, 2036.
Following these awards, Paya directly holds 6,856 shares of Common Stock and has 5,625 shares held indirectly through a family trust.
Vaxcyte director Olivier Brandicourt received new equity awards consisting of restricted stock units (RSUs) and stock options. He was granted 2,194 RSUs, each representing one share of Vaxcyte common stock. These RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual stockholder meeting, subject to his continuous service.
He also received stock options for 11,034 shares of common stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These options vest monthly and will be fully vested on the same earlier-of-2027-or-next-meeting schedule. Following the RSU grant, he directly holds 4,699 common shares.
Vaxcyte, Inc. director John Furey received equity awards as part of his compensation. He acquired 2,265 shares of Common Stock in the form of restricted stock units that will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to his continuous service. Following this grant, he directly holds 5,306 shares of Common Stock.
Furey also received a stock option for 11,389 shares of Common Stock at an exercise price of $49.56 per share, expiring on June 15, 2036. These option shares vest monthly and will be fully vested on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to his continued service.